Intratumoural administration and tumour tissue targeting of cancer immunotherapiesIgnacio Melero, Aurélien Marabelle|Nature Reviews Clinical Oncology|2021Cited by 469
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockadeNicolas Jacquelot, Laurence Zitvogel, Takahiro Yamazaki et al.|Cell Research|2019Cited by 246
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.Hyun Cheol Chung, Sarina A. Piha‐Paul, José A. López-Martín et al.|Journal of Clinical Oncology|2018Cited by 208
Predictors of responses to immune checkpoint blockade in advanced melanomaNicolas Jacquelot, Laurence Zitvogel, María P. Roberti et al.|Nature Communications|2017Cited by 201
How to manage patients with corticosteroids in oncology in the era of immunotherapy?Mihaela Aldea, Jean‐Marie Michot, Émeline Orillard et al.|European Journal of Cancer|2020Cited by 87